Literature DB >> 16604304

Association study of polymorphisms in glycine transporter with schizophrenia.

S-J Tsai1, C-Y Cheng, C-J Hong, D-L Liao, S-J Hou, F-C Yen, Y-J Liou.   

Abstract

Glycine acts as an obligatory co-agonist with glutamate on N-methyl-D-aspartate (NMDA) receptors. Brain glycine availability is determined by glycine transporters (GlyT1 or SLC6A9), which mediate glycine reuptake into nerve terminals. Since hypofunction of NMDA receptors has been implicated in the pathophysiology of schizophrenia, this study tests the hypothesis that GlyT1 genetic variants confer susceptibility to schizophrenia. Four GlyT1 polymorphisms were studied in a sample population of 249 people with schizophrenia and 210 normal controls. One polymorphism (rs16831541) was not informative in our Chinese population while the other three polymorphisms (rs1766967, rs2248632 and rs2248253) were analysed with chi-square tests and haplotype analysis. Significant linkage disequilibrium was obtained among the three polymorphisms. Neither single marker nor haplotype analysis revealed an association between variants at the GlyT1 locus and schizophrenia, suggesting that it is unlikely that the GlyT1 polymorphisms investigated play a substantial role in conferring susceptibility to schizophrenia in the Chinese population. Further studies with other GlyT1 variants, relating either to schizophrenia, psychotic symptoms or to therapeutic response in schizophrenia, are suggested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604304     DOI: 10.1007/s00702-006-0438-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  13 in total

1.  Study of a new schizophrenomimetic drug; sernyl.

Authors:  E D LUBY; B D COHEN; G ROSENBAUM; J S GOTTLIEB; R KELLEY
Journal:  AMA Arch Neurol Psychiatry       Date:  1959-03

2.  Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes.

Authors:  K M Kim; S F Kingsmore; H Han; T L Yang-Feng; N Godinot; M F Seldin; M G Caron; B Giros
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

3.  Provocative tests with psychostimulant drugs in schizophrenia.

Authors:  J A Lieberman; J M Kane; J Alvir
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Effects of typical and atypical antipsychotics on human glycine transporters.

Authors:  Jacinta B Williams; Pierre J Mallorga; P Jeffrey Conn; Douglas J Pettibone; Cyrille Sur
Journal:  Schizophr Res       Date:  2004-11-01       Impact factor: 4.939

5.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

Review 6.  Ionotropic glutamate receptors as therapeutic targets in schizophrenia.

Authors:  Joseph T Coyle; Guochuan Tsai; Donald C Goff
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-04

7.  Gene knockout of glycine transporter 1: characterization of the behavioral phenotype.

Authors:  Guochuan Tsai; Rebecca J Ralph-Williams; Marzia Martina; Richard Bergeron; Joanne Berger-Sweeney; Kevin S Dunham; Zhichun Jiang; S Barak Caine; Joseph T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-24       Impact factor: 11.205

8.  Association study of PICK1 rs3952 polymorphism and schizophrenia.

Authors:  Chen-Jee Hong; Ding-Lieh Liao; Hao-Ling Shih; Shih-Jen Tsai
Journal:  Neuroreport       Date:  2004-08-26       Impact factor: 1.837

9.  Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.

Authors:  Guochuan Tsai; Hsien-Yuan Lane; Pinchen Yang; Mian-Yoon Chong; Nicholas Lange
Journal:  Biol Psychiatry       Date:  2004-03-01       Impact factor: 13.382

10.  Glycine potentiates the NMDA response in cultured mouse brain neurons.

Authors:  J W Johnson; P Ascher
Journal:  Nature       Date:  1987 Feb 5-11       Impact factor: 49.962

View more
  5 in total

1.  Does aberrant membrane transport contribute to poor outcome in adult acute myeloid leukemia?

Authors:  Alexandre Chigaev
Journal:  Front Pharmacol       Date:  2015-07-02       Impact factor: 5.810

2.  Association study of polymorphisms in post-synaptic density protein 95 (PSD-95) with schizophrenia.

Authors:  S-J Tsai; C-J Hong; C-Y Cheng; D-L Liao; Y-J Liou
Journal:  J Neural Transm (Vienna)       Date:  2006-11-10       Impact factor: 3.575

Review 3.  Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.

Authors:  Andrea de Bartolomeis; Mirko Manchia; Federica Marmo; Licia Vellucci; Felice Iasevoli; Annarita Barone
Journal:  Front Psychiatry       Date:  2020-05-14       Impact factor: 4.157

4.  Association Study of the SLC1A2 (rs4354668), SLC6A9 (rs2486001), and SLC6A5 (rs2000959) Polymorphisms in Major Depressive Disorder.

Authors:  Patryk Rodek; Małgorzata Kowalczyk; Jan Kowalski; Aleksander Owczarek; Piotr Choręza; Krzysztof Kucia
Journal:  J Clin Med       Date:  2022-10-07       Impact factor: 4.964

5.  Association study of polymorphisms in the neutral amino acid transporter genes SLC1A4, SLC1A5 and the glycine transporter genes SLC6A5, SLC6A9 with schizophrenia.

Authors:  Xiangdong Deng; Noriaki Sagata; Naoko Takeuchi; Masami Tanaka; Hideaki Ninomiya; Nakao Iwata; Norio Ozaki; Hiroki Shibata; Yasuyuki Fukumaki
Journal:  BMC Psychiatry       Date:  2008-07-18       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.